Understanding of cytokines and targeted therapy in macrophage activation syndrome
Understanding of cytokines and targeted therapy in macrophage activation syndrome
复制标题
DOI：
10.1016/j.semarthrit.2020.12.007
复制
发表时间：
2021-02-01
影响因子：
5
通讯作者：
Fang, Hong
中科院分区：
文献类型：
--
作者：
Tang, Shunli;Li, Sheng;Fang, Hong
巨噬细胞活化综合征（MAS）是全身性自身炎性/自身免疫性疾病（通常为全身性幼年特发性关节炎和成人发病的斯蒂尔病）的潜在危及生命的并发症。其特征在于巨噬细胞和T淋巴细胞的过度增殖。最近的研究表明，细胞因子风暴与升高的促炎细胞因子，包括IFN-γ，IL-18和IL-6，可能是MAS的发病机制的核心。虽然MAS治疗的主流仍然是皮质类固醇和环孢素，但据报道，抗细胞因子生物制剂的靶向治疗有望控制MAS的全身炎症。(C)2020爱思唯尔公司All rights reserved.
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of systemic autoinflammatory/autoimmune diseases, generally systemic juvenile idiopathic arthritis and adult-onset Still's disease. It is characterized by an excessive proliferation of macrophages and T lymphocytes. Recent research revealed that cytokine storm with elevated pro-inflammatory cytokines, including IFN-gamma, IL-18, and IL-6, may be central to the pathogenesis of MAS. Though the mainstream of MAS treatment remains corticosteroids and cyclosporine, targeted therapies with anti-cytokine biologics are reported to be promising for controlling systemic inflammation in MAS. (C) 2020 Elsevier Inc. All rights reserved.